Erythropoiesis‐stimulating agents and other methods to enhance oxygen transport
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Oxygen is essential for life, and the body has developed an exquisite method to collect oxygen in the lungs and transport it to the tissues. Hb contained within red blood cells (RBCs), is the key oxygen‐carrying component in blood, and levels of RBCs are tightly controlled according to demand for oxygen. The availability of oxygen plays a critical role in athletic performance, and agents that enhance oxygen delivery to tissues increase aerobic power. Early methods to increase oxygen delivery included training at altitude, and later, transfusion of packed RBCs. A breakthrough in understanding how RBC formation is controlled included the discovery of erythropoietin (Epo) and cloning of the EPO gene. Cloning of the EPO gene was followed by commercial development of recombinant human Epo (rHuEpo). Legitimate use of this and other agents that affect oxygen delivery is important in the treatment of anaemia (low Hb levels) in patients with chronic kidney disease or in cancer patients with chemotherapy‐induced anaemia. However, competitive sports was affected by illicit use of rHuEpo to enhance performance. Testing methods for these agents resulted in a cat‐and‐mouse game, with testing labs attempting to detect the use of a drug or blood product to improve athletic performance (doping) and certain athletes developing methods to use the agents without being detected. This article examines the current methods to enhance aerobic performance and the methods to detect illicit use. British Journal of Pharmacology(2008)154, 529–541; doi:fn1; published online 24 March 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 2×
“Hydroxylated HIF is ubiquitinylated by a ligase forming a complex with von Hippel–Lindau protein, which targets HIF for degradation by the proteosome (Ivan et al., 2001; Maxwell et al., 2001; Hon et al., 2002).”
BackgroundEpstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1
Jiang, B.-H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17771 · Cited by 1,106 · cited 1×
“Hypoxiainducible factor (HIF) is a heterodimer comprised of a- and b-subunits and is a positive regulatory protein for EPO gene expression (Wang et al., 1995; Jiang et al., 1996).”
BackgroundMasson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5197 · Cited by 1,014 · cited 1×
“An O2dependent enzyme, (HIF-prolyl hydroxylase; HIF-PH) hydroxylates HIF at specific prolines contained in O2 degradation domains (Bruick and McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001; Masson et al., 2001).”
BackgroundEschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
Ang, S. O., Chen, H., Hirota, K., Gordeuk, V. R., Jelinek, J., Guan, Y., Liu, E., Sergueeva, A. I., Miasnikova, G. Y., Mole, D., et al. (2002) · Nature Genetics · doi:10.1038/ng1019 · Cited by 510 · cited 1×
“These subjects have an altered response to O2 due to a mutation in VHL, a protein important in the regulation of the transcription factor that controls synthesis of several genes including eEpo (Ang et al., 2002).”
BackgroundIron, oxidative stress and human health
Puntarulo, S. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.001 · Cited by 348 · cited 1×
“Elevated iron may also increase susceptibility to infection and enhance virulence of some bacterial pathogens (Kletzmayr et al., 2002; Puntarulo, 2005; Bullen et al., 2006; McCullough and Bartfay, 2007).”
BackgroundNatural resistance, iron and infection: a challenge for clinical medicine
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46386-0 · Cited by 163 · cited 1×
“Elevated iron may also increase susceptibility to infection and enhance virulence of some bacterial pathogens (Kletzmayr et al., 2002; Puntarulo, 2005; Bullen et al., 2006; McCullough and Bartfay, 2007).”
Background2-Oxoglutarate analogue inhibitors of hif prolyl hydroxylase
Mole, D. R., Schlemminger, I., McNeill, L. A., Hewitson, K. S., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00539-0 · Cited by 145 · cited 1×
“Attempts to discover and develop more specific and safe HIF-PH inhibitors have been described (Mole et al., 2003).”
BackgroundMcCullough, K. D., & Bartfay, W. J. (2007) · Biological Research For Nursing · doi:10.1177/109980040629873 · Cited by 17
Cited by
Pope, H. G., Wood, R. I., Rogol, A., Nyberg, F., Bowers, L., & Bhasin, S. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1058 · Cited by 658
Bunn, H. F. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011619 · Cited by 234
Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia
Soni, H. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.02.008 · Cited by 21
“inhibitors may lead to relatively small increase in EPO blood levels [35].”
BackgroundUrdampilleta, A., López-Grueso, R., Martínez-Sanz, J. M., & Mielgo-Ayuso, J. (2014) · Revista Española de Nutrición Humana y Dietética · doi:10.14306/renhyd.18.3.24 · Cited by 8
Metadata
- Authors
- Elliott, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-06
- Volume
- 154
- Issue
- 3
- Pages
- 529-541
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2053443925
- Cited by
- 126
- References
- 12
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.